 SHANGHAI, March 25, 2021 PRNewswire -- 111, Inc. 111 or the Company Nasdaq: YI, a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, and Jianming Pharmaceutical Group Jianming Pharmaceutical, a pharmaceutical manufacturer of liver and gallbladder medications, have entered into a strategic cooperation agreement to develop an online chronic disease management platform for the hepatobiliary disease market in China. As part of the agreement, Jianming Pharmaceuticals liver and gallbladder medications will be available on 111s network, initially leveraging its SMART supply chain services to distribute products in Fujian province, and eventually expanding to the out-of-hospital market nationwide. 